SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-066233
Filing Date
2023-08-11
Accepted
2023-08-11 16:05:43
Documents
15
Period of Report
2023-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea183229-8k_jasperthera.htm   iXBRL 8-K 35405
2 PRESS RELEASE, DATED AUGUST 11, 2023 ea183229ex99-1_jasperthera.htm EX-99.1 75449
7 GRAPHIC ex99-1_001.jpg GRAPHIC 4900
  Complete submission text file 0001213900-23-066233.txt   349227

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE jspr-20230811.xsd EX-101.SCH 3928
4 XBRL DEFINITION FILE jspr-20230811_def.xml EX-101.DEF 26833
5 XBRL LABEL FILE jspr-20230811_lab.xml EX-101.LAB 37093
6 XBRL PRESENTATION FILE jspr-20230811_pre.xml EX-101.PRE 25457
9 EXTRACTED XBRL INSTANCE DOCUMENT ea183229-8k_jasperthera_htm.xml XML 5621
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 231164017
SIC: 2836 Biological Products, (No Diagnostic Substances)